Nitric Acid

Nitric Acid

SCHEMBL4160107

CC(=O)NCc1ccc(NC(=N)N)cc1.O=[N+]([O-])O

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ERG11

The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.47
KMT2A Q03164 2/20 0.45
NPC1 O15118 2/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
ALDH1A1 P00352 3/20 0.42
RAB9A P51151 2/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
EPHX2 P34913 1/20 0.42
NR1H4 Q96RI1 1/20 0.42
MEN1 O00255 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
PPID Q08752 1/20 0.40
F7 P08709 1/20 0.40
LMNA P02545 1/20 0.39
RORC P51449 1/20 0.39
AOC3 Q16853 1/20 0.38
GLA P06280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4165820 0.91 PTPN1 (0.54) PTPN1KMT2ANPC1HDAC1HDAC6
Nitric Acid SCHEMBL2073972 0.84 SMN1; SMN2 (0.44) KMT2AALDH1A1POLBMAPTMEN1
Nitric Acid SCHEMBL2073717 0.84 KMT2A (0.50) KMT2AALDH1A1RAB9AMAPTNR1H4
SCHEMBL7446619 0.77 NPC1 (0.51) PTPN1KMT2ANPC1RAB9APOLB
SCHEMBL3735282 0.77 PTPN1 (0.72) PTPN1KMT2ANPC1HDAC1HDAC6
SCHEMBL14524510 0.77 NPC1 (0.44) PTPN1KMT2ANPC1ALDH1A1RAB9A
Nitric Acid SCHEMBL2076135 0.77 TSHR (0.49) KMT2AHDAC6ALDH1A1MAPTMEN1
SCHEMBL7688793 0.76 PTPN1 (0.54) PTPN1KMT2ANPC1HDAC1HDAC6
Nitric Acid SCHEMBL2073971 0.76 MEN1 (0.41) KMT2ANPC1ALDH1A1RAB9APOLB
Nitric Acid SCHEMBL9982936 0.76 LMNA (0.49) KMT2ANPC1ALDH1A1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
EP-1756098-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2007-02-28 EP disclosed
WO-2005116025-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CDK2, CDK4, CDK20 PTPN1 1170/4885KMT2A 1239/4885NPC1 2382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.